drugset
drugset / Trial / NCT06355908

IL13Rα2 CAR-T for Patients With r/r Glioma

NCT06355908 ↗

Phase 1 Suspended 30 enrolled Yang Zhang TCRCure Biopharma Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.

Timeline

Start
2024-03-21
Primary completion
2026-05-01
Completion
2027-05-01

Outcome

Outcome not reported

Stopped: “Temporarily suspended for HGRAC filing requirements”

Drugs

EvaluationDrugModalityDoseRoute
Subject IL13Rα2 CAR-T Cell therapy — Other

Indications

glioma